Pulsed source of spectrally uncorrelated and indistinguishable photons at telecom wavelengths

We report on the generation of indistinguishable photon pairs at telecom wavelengths based on a type-II parametric down conversion process in a periodically poled potassium titanyl phosphate (PPKTP) crystal. The phase matching, pump laser characteristics and coupling geometry are optimised to obtain spectrally uncorrelated photons with high coupling efficiencies. Four photons are generated by a counter- propagating pump in the same crystal and anlysed via two photon interference experiments between photons from each pair source as well as joint spectral and g^(2) measurements. We obtain a spectral purity of 0.91 and coupling efficiencies around 90% for all four photons without any filtering. These pure indistinguishable photon sources at telecom wavelengths are perfectly adapted for quantum network demonstrations and other multi-photon protocols

High coherence photon pair source for quantum communication

This paper reports a novel single mode source of narrow-band entangled photon pairs at telecom wavelengths under continuous wave excitation, based on parametric down conversion. For only 7 mW of pump power it has a created spectral radiance of 0.08 pairs per coherence length and a bandwidth of 10 pm (1.2 GHz). The effectively emitted spectral brightness reaches 3.9*10^5 pairs /(s pm). Furthermore, when combined with low jitter single photon detectors, such sources allow for the implementation of quantum communication protocols without any active synchronization or path length stabilization. A HOM-Dip with photons from two autonomous CW sources has been realized demonstrating the setup's stability and performance.Comment: 12 pages, 4 figure

Universal quantum computation and simulation using any entangling Hamiltonian and local unitaries

What interactions are sufficient to simulate arbitrary quantum dynamics in a composite quantum system? We provide an efficient algorithm to simulate any desired two-body Hamiltonian evolution using any fixed two-body entangling n-qubit Hamiltonian and local unitaries. It follows that universal quantum computation can be performed using any entangling interaction and local unitary operations.Comment: Added references to NMR refocusing and to earlier work by Leung et al and Jones and Knil

Interaction of Independent Single Photons based on Integrated Nonlinear Optics

Photons are ideal carriers of quantum information, as they can be easily created and can travel long distances without being affected by decoherence. For this reason, they are well suited for quantum communication. However, the interaction between single photons is negligible under most circumstances. Realising such an interaction is not only fundamentally fascinating but holds great potential for emerging technologies. It has recently been shown that even weak optical nonlinearities between single photons can be used to perform important quantum communication tasks more efficiently than methods based on linear optics, which have fundamental limitations. Nonlinear optical effects at single photon levels in atomic media have been studied and demonstrated but these are neither flexible nor compatible with quantum communication as they impose restrictions on photons' wavelengths and bandwidths. Here we use a high efficiency nonlinear waveguide to observe the sum-frequency generation between a single photon and a single-photon level coherent state from two independent sources. The use of an integrated, room-temperature device and telecom wavelengths makes this approach to photon-photon interaction well adapted to long distance quantum communication, moving quantum nonlinear optics one step further towards complex quantum networks and future applications such as device independent quantum key distribution

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.

Background: Apolipoprotein B (apoB) provides an integrated measure of atherogenic risk. Whether apoB levels and apoB lowering hold incremental predictive information on residual risk after acute coronary syndrome beyond that provided by low-density lipoprotein cholesterol is uncertain. Methods: The ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) compared the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome and elevated atherogenic lipoproteins despite optimized statin therapy. Primary outcome was major adverse cardiovascular events (MACE; coronary heart disease death, nonfatal myocardial infarction, fatal/nonfatal ischemic stroke, hospitalization for unstable angina). Associations between baseline apoB or apoB at 4 months and MACE were assessed in adjusted Cox proportional hazards and propensity score–matched models. Results: Median follow-up was 2.8 years. In proportional hazards analysis in the placebo group, MACE incidence increased across increasing baseline apoB strata (3.2 [95% CI, 2.9–3.6], 4.0 [95% CI, 3.6–4.5], and 5.5 [95% CI, 5.0–6.1] events per 100 patient-years in strata 35–<50, and ≤35 mg/dL, respectively). Compared with propensity score–matched patients from the placebo group, treatment hazard ratios for alirocumab also decreased monotonically across achieved apoB strata. Achieved apoB was predictive of MACE after adjustment for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol but not vice versa. Conclusions: In patients with recent acute coronary syndrome and elevated atherogenic lipoproteins, MACE increased across baseline apoB strata. Alirocumab reduced MACE across all strata of baseline apoB, with larger absolute reductions in patients with higher baseline levels. Lower achieved apoB was associated with lower risk of MACE, even after accounting for achieved low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol, indicating that apoB provides incremental information. Achievement of apoB levels as low as ≤35 mg/dL may reduce lipoprotein-attributable residual risk after acute coronary syndrome. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01663402.gov; Unique identifier: NCT01663402.URL: https://www